Dana-Farber Cancer Institute | Strategic Alliance Partners

December 04, 2019

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

November 02, 2019

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

October 26, 2019

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.

October 23, 2019

Kathleen Mahoney, MD, PhD, discusses the potential of targeting V-domain immunoglobulin containing suppressor of T-cell activation in renal cell carcinoma.

October 21, 2019

Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma.

October 09, 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

October 02, 2019

Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.

September 25, 2019

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

September 23, 2019

Wayne A. Marasco, MD, PhD, discusses the intricacy of engineering CAR T cells and the early data he has observed with CAR T-cell therapy in renal cell carcinoma.

September 17, 2019

Toni Choueiri, MD, discusses the rationale behind the Kidney Cancer Research Summit and recent advances in the renal cell carcinoma landscape.

September 16, 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.

September 11, 2019

Toni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.

July 25, 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

July 24, 2019

Paul G. Richardson, MD, reviews the results of the phase III ICARIA-MM trial as well as preliminary data regarding melflufen in relapsed/refractory multiple myeloma.

July 24, 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of radiopharmaceuticals in the treatment of patients with prostate cancer.

July 24, 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses emerging immunotherapy approaches in bladder cancer.

July 24, 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma.

July 16, 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses the next generation of trials in renal cell carcinoma (RCC).

July 11, 2019

Toni Choueiri, MD, discusses the use of checkpoint inhibitors to treat patients with sarcomatoid carcinoma.

July 10, 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses the frontline combination therapies that are available for the treatment of patients with metastatic renal cell carcinoma (mRCC).